Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial (May, 10.1016/S2213-2600(20)30154-5, 2020)

首页> 外文期刊>The lancet. Respiratory medicine. >Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial (May, 10.1016/S2213-2600(20)30154-5, 2020)

【24h】

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial (May, 10.1016/S2213-2600(20)30154-5, 2020)

机译：Tepotinib Plus Gefitinib患者EGFR-突变体非小细胞肺癌，具有过表达或达到扩增和获得前期EGFR抑制剂的抗性（见解研究）：开放标签，阶段1B / 2，多期，随机试验（5月，10.1016 / s2213-2600（20）30154-5,2020）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet. Respiratory medicine.》 |2020年第7期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词

相似文献

外文文献

1. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial (May, 10.1016/S2213-2600(20)30154-5, 2020) [J] . The lancet. Respiratory medicine. . 2020,第7期

机译：Tepotinib Plus Gefitinib患者EGFR-突变体非小细胞肺癌，具有过表达或达到扩增和获得前期EGFR抑制剂的抗性（见解研究）：开放标签，阶段1B / 2，多期，随机试验（5月，10.1016 / s2213-2600（20）30154-5,2020）
2. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial [J] . Yang Jin-Ji, Zhou Caicun, Huang Yisheng, The lancet. Respiratory medicine. . 2017,第9期

机译：icotinib与EGFR-突变体非小细胞肺癌和多脑转移患者的全脑照射（大脑）：多期，第3阶段，开放标签，平行，随机对照试验
3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [J] . Park Keunchil, Tan Eng-Huat, OByrne Ken, The lancet oncology . 2016,第5期

机译：阿法替尼与吉非替尼作为EGFR突变阳性非小细胞肺癌（LUX-Lung 7）患者的一线治疗：2B期，开放标签，随机对照试验
4. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre open-label phase 1b trial [O] . James L. Gulley, Arun Rajan, David R. Spigel, -1

机译：Avelumab用于先前已治疗的转移性或复发性非小细胞肺癌（JAVELIN实体瘤）患者：一项多中心开放标签1b期临床试验的剂量扩展队列
5. 1415TiP INSIGHT 2: Tepotinib + osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp) [O] . E.F. Smit, E. Felip, N. Karachaliou, 2020

机译：1415TIP Insight 2：Tepotinib + Osimertinib在患者（PTS）中，具有EGFR-突变体NSCLC由于达到扩增（Metamp）而获得对第一线Osimertinib的抗性

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial (May, 10.1016/S2213-2600(20)30154-5, 2020)

著录项

相似文献

相关主题

期刊订阅